Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy

Neoadjuvant platin-based therapy is accepted as a standard therapy for advanced esophageal adenocarcinoma (EAC). Patients who respond have a better survival prognosis, but still a significant number of responder patients die from tumor recurrence. Molecular markers for prognosis in neoadjuvantly tre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Aichler, Michaela, Motschmann, Martin, Jütting, Uta, Luber, Birgit, Becker, Karen, Ott, Katja, Lordick, Florian, Langer, Rupert, Feith, Marcus, Siewert, Jörg Rüdiger, Walch, Axel
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2014
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4196151/
https://ncbi.nlm.nih.gov/pubmed/25216514
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars